OBJECTIVES: The objective of this study is to compare the HTA decisions of oncology products in France and Germany and provide insight into the most important asset value attributes that characterise a positive appraisal in these markets. METHODS: We analysed the G-BA and the HAS assessments of 11 oncology products published since January 1^st, 2011.The correlation coefficient was calculated to assess the linear correlation of the additional clinical benefit of an oncology product evaluated by the G-BA and the HAS, both measured by an arbitrary score scale from 1 (best outcome) to 5 (worst outcome). The G-BA score was taken from the “added benefit” rating, and the HAS score was determined by the ASMR rating. The additional clinical benefit is determined by the clinical data (efficacy, safety and QoL) provided in both GER and FRA. The correlation coefficient between the incremental OS benefit and the HTA appraisal outcome in each market was also calculated. RESULTS: The correlation coefficient of HTA decisions by the G-BA and the HAS for oncology products is 0.73. In Germany, the magnitude of incremental OS benefit negatively correlates with the G-BA score (correlation coefficient = -0.83). Similar results were also observed in France, where the correlation coefficient between the incremental OS benefit and the HAS score was -0.66. Interestingly, the G-BA score forms clear “steps” that highly correlate with the incremental OS benefit based on our empirical analysis. To “step up” from score 3 to score 2, an incremental OS benefit of 3 months appears to serve as a threshold.  CONCLUSIONS: The negative linear correlation between the incremental OS benefit and the HTA rating in GER and FRA suggests that the additional clinical benefit, especially the incremental OS benefit is a major factor in determining the HTA outcome in GER and FRA.